Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma

Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma - a Randomized Controlled Trial

60 patients of radiological, biopsy proven advanced HCC (Hepatocellular carcinoma) patient will be randomized into two groups. Cases group will receive Sorafenib plus vitamin K and control group will receive Sorafenib plus placebo

Inclusion Criteria:

• Age 18 to 70 years
• Child A and B cirrhosis with hepatocellular carcinoma
• Biochemical, Radiological, histological evidence of advanced hepatocellular carcinoma diagnosed as stage C and stage d with serum bilirubin <5 mg/dl according to BCLC staging system
• HCC with portal vein thrombosis
• Unresectable cancer, as assessed carefully by individual experts
• No recent active treatment like surgery, radiofrequency ablation, trans arterial chemo embolization, radiotherapy, chemotherapy (within the past 6 months)

Exclusion Criteria:

• Patients with end-stage hepatocellular carcinoma (Stage D, BCLC)with poor performance status
• Child C cirrhosis with HCC (Hepatocellular carcinoma)
• HCC with acute decompensated state of CLD - GI bleed, increased jaundice, HE, SBP (Spontaneous Bacterial Peritonitis)
• Acute febrile illness
• Pregnancy or lactation